In women, naturally induced anti-HPV serum antibodies are a likely marker of host im-2 mune protection against subsequent HPV acquisition and progression to precancerous lesions 3 and cancers. However, it is unclear whether the same is the case in men. In this study, we as-4 sessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 5 in relation to baseline serostatus in a cohort of 2187 men over a 48-month period. Genital 6 swabs were collected every 6 months and tested for HPV presence. Incidence proportions by 7 serostatus were calculated at each study visit to examine whether potential immune protection 8 attenuated over time. Overall, incidence proportions did not differ statistically between baseline 9 seropositive and seronegative men at any study visit or over the follow-up period. The risk of 10 incident and 6-month persistent infection was not associated with baseline serostatus or base-11 line serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in 12 men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent se-13 rum antibodies induced by prior infection may not be a suitable marker for subsequent immune 14 protection against genital HPV16 acquisition in men. 15 16 PRECIS: There appear to be differences in the way that men and women react to prior HPV 17 exposure, such that the presence of HPV serum antibodies offer a suitable marker to predict 18 immune protection against future genital infections in women, but not in men. Research.
Interviewing (CASI) system. 10ml venous blood was collected for serum antibody testing and 1 the external genitalia were sampled for HPV testing by study clinicians. The informed consent 2 and the study protocol were reviewed and approved by appropriate internal review boards and 3 human subject committees at each study site. absorbance value was used as the cut point for seropositivity. Quality control of the serology 1 assays was assured by inclusion of laboratory-prepared seropositive and seronegative controls 2 in each run of the assay. No blind replicates of serum samples were generated to estimate with-3 in-and between-batch reliability. However, the laboratory staff were blind to HPV DNA status of 4 individuals whose serum samples were to be tested for serum antibodies. 5 HPV DNA Sampling and Testing. Three pre-wetted Dacron swabs were used to col-6 lect exfoliated skin cells from the penis and scrotum and later combined to form a single speci-7 men. All specimens were stored at -70°C until PCR analyses and genotyping were conducted. 8 DNA was extracted from exfoliated skin cell samples using the QIAamp DNA Mini Kit (QIAGEN, 9
Valencia, CA) and tested for HPV DNA using polymerase chain reaction (PCR) for amplification 10 of a fragment of the HPV L1 gene (37) . HPV genotyping was conducted using the Linear Array 11 HPV Genotyping Protocol (Roche Diagnostics, Indianapolis, IN) to detect 37 genital HPV types 12 (38) . Human β-globin was tested to assure the integrity of DNA, and was detected in 94.9% 13 inter-quartile range: 1.2-3.0). The median interval between visits was 6.2 months. 8
Characteristics of seronegative men and seropositive men are summarized in Table 1 . 9
Baseline seroprevalence of HPV 16 was 12.3% overall, 10.0% among MSW and 31.2% among 10 MSM. Overall, seronegative and seropositive men differed significantly by age at enrollment, 11 country of residence, the number of lifetime sex partners (either sex) and new sex partners (ei-12 ther sex) in the past 6 months. Seropositive men were more likely to be ≥25 years, Brazilian, 13
and have a large number of lifetime sex partners and two or more new sex partners in past 6 14 months. Similarly, significant differences were observed in age at enrollment, country of resi-15 dence, and the number of lifetime sex partners (either sex) and lifetime female sex partners be-16 tween seronegative and seropositive MSW. Among MSM, seropositive men were significantly 17 older compared to seronegative men at enrollment. 18
Overall, a total of 221 (10.1%) men developed incident HPV 16 infections (9.8% of sero-19 negative men vs. 12.6% of seropositive men), and 72 (3.9%) men developed 6-month persistent 20 HPV 16 infections (3.9% of seronegative men vs. 3.8% of seropositive men) during the study 21 period. Timing of incident and 6-month persistent HPV 16 detection over the study period is 22 summarized in Table 2 3.1 vs. 5.8%). The differences, though more apparent among MSM, were not statistically signifi-2 cant. However, the reduction in HPV 16 incidence was not sustained throughout the study pe-3 riod. Likewise, seropositive MSM had a lower incidence of 6-month persistent HPV 16 infection 4 than seronegative MSM (6 month visit: 0 vs. 2.1%; 12 month visit: 1.5 vs. 2.8%) in the first year 5 which was not retained for the remaining study period. 6
The risk of incident HPV 16 infection and 6-month persistent infection according to base-7 line serostatus is presented in Table 3 No protection against 6-month persistent HPV 16 infection was observed among MSW. 21 We further determined if the associations between baseline serostatus and HPV 16 inci-22 dence were impacted by the inclusion of potentially reactivated latent infections from the base-23 line. We re-assessed the risk of incident and 6-month persistent HPV 16 infection in association 24 with baseline serostatus after restricting incident HPV infections to those that showed ≥2 prior 25
Research. 
consecutive, negative HPV 16 DNA results (Table 4 ). The associations in the restricted analysis 1 were consistent with the previous analysis and demonstrated no statistical significance. 2 Additionally, we evaluated if higher serum antibody levels were associated with a lower 3 likelihood of subsequent HPV 16 infection. We did not observe significant associations between 4 serum antibody levels and risk of incident HPV 16 infection or 6-month persistent HPV 16 infec-5 tion for the overall cohort, MSW or MSM (Appendix B). Nor did we observe significant associa-6 tions after we restricted the analysis to seropositive men only (data not shown). 7
Associations of enrollment HPV 16 serostatus with the risk of group-specific HPV infec-8 tion (alpha-9 HPV, alpha-9 HPV excluding HPV 16, and other HPV) were also examined. No 9 cross-protection of HPV 16 enrollment serostatus against group-specific HPV infection was ob-10 served (data not shown). 11
DISCUSSION 12
In this multi-national prospective study of healthy men, we assessed the risk of genital 13 around the cut-point throughout the study period (39) . Similarly, Ho et al reported that for female 10 university students who tested seropositive at least once during the study period, the cumulative 11 probabilities of losing anti-HPV 16 IgG seropositivity by 12, 24 and 36 months were 38.5%, 40.0% 12 and 48.2% (40) . These findings suggest that while the observed difference in incidence over 13 time between seropositive and seronegative men in our study could be due to chance alone, it 14 could also be explained by the loss of serum antibodies over time. The latter possibility, howev-15 er, must be tested in future studies where repeated measurements of serum antibody and DNA 16 status are available. 
direct-binding ELISA assay used in the current study measures total type-specific binding IgG 1 antibodies, including neutralizing and non-neutralizing antibodies; while the competitive neutrali-2 zation assay utilized by Velicer et al (27) measures IgG antibodies that bind to known neutraliz-3 ing epitopes in HPV viral capsid. The inclusion of non-neutralizing antibodies in the present 4 study could have led to overestimation of functional neutralizing antibody levels, and biased the 5 association of protection toward the null. Another explanation for the inconsistent results ob-6 served could be that prolonged presence of serum antibodies had played a role in conferring 7
protection. The protective effect of serum antibodies reported by Ho et al. was only restricted to 8 women who demonstrated high antibody level at ≥2 consecutive visits using a direct ELISA as-9 say (25). Conversely, no protection was detected in other studies of women that determined se-10 rostatus only once at the baseline using a similar assay (41, 42). 11
The assumption of incidence in the present study was largely based on a single negative 12 confirmation of active infection (46) . Furthermore, reactivated latent infection may present low 1 level of viral load or a short time frame for detection. These technical and logistic challenges 2 need to be addressed in future studies. 3
The present study is unique in its longitudinal design, the size of cohort, the long dura-4 tion of follow-up completed for a large percent of participants, and the availability of repeated 5 measurements of HPV 16 DNA status. Yet a few limitations must be addressed. We used a less 6 conservative definition of antibody presence than Ho et al. that required a single detection of 7 seropositivity at enrollment. Due to waning antibody response, time lags in antibody develop-8 ment following infection and generally less than 100% seroconversion rate, some men who had 9 been previously exposed to HPV 16 and as a result had acquired immunity, were likely to have 10 been protected but misclassified as seronegative men. Furthermore, there could be possible 11 misclassification of HPV infection status in the presence of low viral load, both among seroposi-12 tive and seronegative men. The misclassification of both baseline serostatus and HPV 16 infec-13 tion status may have contributed to the null association observed. Finally, despite the relatively 14 large sample size, our stratified analyses were statistically underpowered to obtain stable esti-15 mates of time-specific incidence and to detect potential associations of HPV 16 acquisition with 16 baseline serostatus among MSM due to low incidence of HPV 16 and the small proportion of 17 MSM in the current study. 18
In conclusion, our data showed that in the cohort of 2187 healthy men, the presence of 
